Circulating <scp>CD22</scp>+/<scp>CD19</scp>−/<scp>CD24</scp>− progenitors and <scp>CD22</scp>+/<scp>CD19</scp>+/<scp>CD24</scp>− mature B cells: Diagnostic pitfalls for minimal residual disease detection in <scp>B‐lymphoblastic</scp> leukemia
Ting Zhou(Memorial Sloan Kettering Cancer Center), Hao‐Wei Wang(Fu Jen Catholic University), Truc Ho(National Institutes of Health), Nirali N. Shah(National Institutes of Health), Jeremiah Karrs(Dartmouth College), Alyssa Doverte(National Institutes of Health), James N. Kochenderfer(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 9
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Long-term outcomes following CAR T cell therapy: what we know so far
|Nature Reviews Clinical Oncology|2023|1.2k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422